129 related articles for article (PubMed ID: 18687167)
1. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis.
Marini F; Falchetti A; Silvestri S; Bagger Y; Luzi E; Tanini A; Christiansen C; Brandi ML
Curr Med Res Opin; 2008 Sep; 24(9):2609-15. PubMed ID: 18687167
[TBL] [Abstract][Full Text] [Related]
2. Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Liu Y; Liu H; Li M; Zhou P; Xing X; Xia W; Zhang Z; Liao E; Chen D; Liu J; Tao T; Wu W; Xu L
Chin Med J (Engl); 2014; 127(4):662-8. PubMed ID: 24534219
[TBL] [Abstract][Full Text] [Related]
3. Effects of differences in polymorphism of gene encoding enzyme faenesyl diphosphate synthase (FDPS), rs2297480, on bone mineral density and biochemical markers of bone turnover in Thai postmenopausal women.
Songpatanasilp T; Chanprasertyothin S
J Med Assoc Thai; 2011 Oct; 94 Suppl 5():S38-46. PubMed ID: 22338925
[TBL] [Abstract][Full Text] [Related]
4. Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates.
Olmos JM; Zarrabeitia MT; Hernández JL; Sañudo C; González-Macías J; Riancho JA
Pharmacogenomics J; 2012 Jun; 12(3):227-32. PubMed ID: 21151198
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women.
Choi HJ; Choi JY; Cho SW; Kang D; Han KO; Kim SW; Kim SY; Chung YS; Shin CS
Yonsei Med J; 2010 Mar; 51(2):231-8. PubMed ID: 20191015
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin.
Pérez-Castrillón JL; Zarrabeitia MT; Abad L; Vega G; Ruiz-Mambrilla M; Gonzalez-Sagredo M; Dueñas-Laita A; Riancho JA
Rheumatol Int; 2014 Aug; 34(8):1073-7. PubMed ID: 24311107
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl Diphosphate Synthase Gene Associated with Loss of Bone Mass Density and Alendronate Treatment Failure in Patients with Primary Osteoporosis.
Guaraná WL; Lima CAD; Barbosa AD; Crovella S; Sandrin-Garcia P
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891810
[TBL] [Abstract][Full Text] [Related]
8. Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women.
Levy ME; Parker RA; Ferrell RE; Zmuda JM; Greenspan SL
Maturitas; 2007 Jul; 57(3):247-52. PubMed ID: 17368768
[TBL] [Abstract][Full Text] [Related]
9. Genetic predictors of skeletal outcomes in healthy fertile women: the Bonturno study.
Massart F; Marini F; Bianchi G; Minisola S; Luisetto G; Pirazzoli A; Salvi S; Micheli D; Miccoli M; Baggiani A; Giusti F; Brandi ML
Joint Bone Spine; 2013 Jul; 80(4):414-9. PubMed ID: 23238007
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of FDPS, LRP5, SOST and VKORC1 genes and their relation with osteoporosis in postmenopausal Romanian women.
Ciubean AD; Ungur RA; Irsay L; Ciortea VM; Borda IM; Dogaru GB; Trifa AP; Vesa SC; Buzoianu AD
PLoS One; 2019; 14(11):e0225776. PubMed ID: 31774873
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
12. Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis.
Marozik P; Alekna V; Rudenko E; Tamulaitiene M; Rudenka A; Mastaviciute A; Samokhovec V; Cernovas A; Kobets K; Mosse I
PLoS One; 2019; 14(8):e0221511. PubMed ID: 31437227
[TBL] [Abstract][Full Text] [Related]
13. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in key bone modulator cytokines genes influence bisphosphonates therapy in postmenopausal women.
Lima CA; Javorski NR; Souza AP; Barbosa AD; Valença AP; Crovella S; Souza PR; De Azevedo Silva J; Sandrin-Garcia P
Inflammopharmacology; 2017 Apr; 25(2):191-201. PubMed ID: 28220389
[TBL] [Abstract][Full Text] [Related]
15. Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY study.
Garnero P; Borel O; Sornay-Rendu E; Duboeuf F; Jeffery R; Woo P; Delmas PD
Bone; 2002 Jul; 31(1):43-50. PubMed ID: 12110411
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.
Marini F; Tonelli P; Cavalli L; Cavalli T; Masi L; Falchetti A; Brandi ML
Front Biosci (Elite Ed); 2011 Jan; 3(1):364-70. PubMed ID: 21196316
[TBL] [Abstract][Full Text] [Related]
17. CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.
Drummond FJ; Mackrill JJ; O'sullivan K; Daly M; Shanahan F; Molloy MG
J Bone Miner Metab; 2006; 24(1):28-35. PubMed ID: 16369895
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
[TBL] [Abstract][Full Text] [Related]
19. Association of transforming growth factor-beta1 (TGFbeta1) T29 --> C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-beta1 in a population-based sample of postmenopausal german women.
Hinke V; Seck T; Clanget C; Scheidt-Nave C; Ziegler R; Pfeilschifter J
Calcif Tissue Int; 2001 Dec; 69(6):315-20. PubMed ID: 11800227
[TBL] [Abstract][Full Text] [Related]
20. Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis.
Morales-Santana S; Díez-Pérez A; Olmos JM; Nogués X; Sosa M; Díaz-Curiel M; Pérez-Castrillón JL; Pérez-Cano R; Torrijos A; Jodar E; Rio LD; Caeiro-Rey JR; Reyes-García R; García-Fontana B; González-Macías J; Muñoz-Torres M
Maturitas; 2015 Dec; 82(4):402-10. PubMed ID: 26358930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
